Gujarat Themis Biosyn to Acquire 100% Stake in MicroBiopharm Japan for JPY 21.5 Billion
Published on: May 22, 2026, 11:42 p.m. | Source: scanx.trade
Gujarat Themis Biosyn Limited has signed a definitive agreement to acquire 100% equity shareholding of MicroBiopharm Japan Co., Ltd. for JPY 21.5 Billion (approximately INR 1,300 Crores), to be funded through a mix of debt and equity. The acquisition will be executed through GTBL's wholly owned Japanese subsidiary, Themis Biosyn Japan Limited, and is expected to close in Q2 FY2027 upon receipt of regulatory approvals, including under Japan's FEFTA. MBJ, with over six decades of fermentation and pharmaceutical manufacturing experience, reported estimated revenue of approximately JPY 9.5 Billion (INR 570 Crores) for FY 2026E. The deal is positioned as a strategic step for GTBL to transition into a technology-driven CDMO platform.
